Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Java 26, due in March with structured concurrency, lazy constants, AOT object caching, and primitive types in patterns, instanceof, and switch, has entered a second rampdown phase for bug fixes. Java ...